Future of cancer incidence in the United States: burdens upon an aging, changing nation.

PURPOSE By 2030, the United States' population will increase to approximately 365 million, including 72 million older adults (age > or = 65 years) and 157 million minority individuals. Although cancer incidence varies by age and race, the impact of demographic changes on cancer incidence has not been fully characterized. We sought to estimate the number of cancer patients diagnosed in the United States through 2030 by age and race. METHODS Current demographic-specific cancer incidence rates were calculated using the Surveillance Epidemiology and End Results database. Population projections from the Census Bureau were used to project future cancer incidence through 2030. RESULTS From 2010 to 2030, the total projected cancer incidence will increase by approximately 45%, from 1.6 million in 2010 to 2.3 million in 2030. This increase is driven by cancer diagnosed in older adults and minorities. A 67% increase in cancer incidence is anticipated for older adults, compared with an 11% increase for younger adults. A 99% increase is anticipated for minorities, compared with a 31% increase for whites. From 2010 to 2030, the percentage of all cancers diagnosed in older adults will increase from 61% to 70%, and the percentage of all cancers diagnosed in minorities will increase from 21% to 28%. CONCLUSION Demographic changes in the United States will result in a marked increase in the number of cancer diagnoses over the next 20 years. Continued efforts are needed to improve cancer care for older adults and minorities.

[1]  G. Vlastos,et al.  Older female cancer patients: importance, causes, and consequences of undertreatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[3]  C. Gross,et al.  Racial disparities in cancer therapy , 2008, Cancer.

[4]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[5]  G. Hortobagyi.  A shortage of oncologists? The American Society of Clinical Oncology workforce study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Xiao-Cheng Wu,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control , 2008, Journal of the National Cancer Institute.

[7]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[8]  Suanna S Bruinooge,et al.  Future supply and demand for oncologists : challenges to assuring access to oncology services. , 2007, Journal of oncology practice.

[9]  D. Berry,et al.  Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Greenwald.  Cancer prevention clinical trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[12]  E. Feuer,et al.  Impact of reporting delay and reporting error on cancer incidence rates and trends. , 2002, Journal of the National Cancer Institute.

[13]  R Yancik,et al.  Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. , 2001, JAMA.

[14]  E. Lamont,et al.  Evaluation of trends in the cost of initial cancer treatment. , 2008, Journal of the National Cancer Institute.

[15]  B. Smedley,et al.  The unequal burden of cancer : an assessment of NIH research and programs for ethnic minorities and the medically underserved , 1999 .

[16]  Elizabeth Eisenhauer,et al.  Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. , 2008, The Lancet. Oncology.

[17]  Theodore T. Suh,et al.  Mentoring junior faculty in geriatric oncology: report from the Cancer and Aging Research Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Eric J Feuer,et al.  The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.

[19]  Kevin Fiscella,et al.  National Cancer Institute Patient Navigation Research Program , 2008, Cancer.

[20]  E. Dunne,et al.  A review of prophylactic human papillomavirus vaccines: Recommendations and monitoring in the US , 2008, Cancer.

[21]  I. Barillot,et al.  Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. , 2001, The New England journal of medicine.

[22]  H. Dombret,et al.  Acute myeloid leukemia in the elderly. , 2008, Seminars in oncology.

[23]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[24]  Great Britain. Foreign Office..  Census of population , 1988 .

[25]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[26]  B. Haffty,et al.  Clinical Outcome and Cosmesis in African‐American Patients Treated with Conservative Surgery and Radiation Therapy , 2003, Cancer journal.

[27]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.